ITC Seeks Public Comment on Potential Section 337 Case on Thyroid Hormone Receptors
Comments are due to the International Trade Commission by Jan. 13 on a potential Section 337 investigation on thyroid hormone receptor-beta agonists, it said in a notice. The notice follows a Dec. 29 complaint by Viking Therapeutics, which seeks to…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
exclude certain selective thyroid hormone receptor-beta agonists of the companies Ascletis Bioscience, Ascletis Pharma, Ascletis Pharmaceuticals and Gannex Pharma, which Viking says import thyroid hormone receptor-beta agonists that use and are made from the "unlawfully misappropriated" trade secrets belonging to Viking. The complaint also names Jinzi "Jason" Wu, founder of Ascletis Pharma, who is currently CEO and chairman of the board. Viking seeks a permanent limited exclusion order, and cease and desist orders.